<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1365-2125</journal-id><journal-id journal-id-type="publisher-id">BCP</journal-id><journal-title-group><journal-title>British Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27275843</article-id><article-id pub-id-type="pmc">5026060</article-id><article-id pub-id-type="doi">10.1111/bcp.13033</article-id><article-id pub-id-type="publisher-id">BCP13033</article-id><article-id pub-id-type="other">MP-00652-15.R2</article-id><article-categories><subj-group subj-group-type="overline"><subject>Clinical Trials</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical Trials</subject></subj-group></article-categories><title-group><article-title>Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure</article-title><alt-title alt-title-type="right-running-head">Cardiovascular effects of urocortin 2 and urocortin 3 in heart failure</alt-title><alt-title alt-title-type="left-running-head">C. G. Stirrat et al.</alt-title></title-group><contrib-group><contrib id="bcp13033-cr-0001" contrib-type="author" corresp="yes"><name><surname>Stirrat</surname><given-names>Colin G.</given-names></name><address><email>colin.stirrat@ed.ac.uk</email></address><xref ref-type="aff" rid="bcp13033-aff-0001">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="bcp13033-note-0001">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="bcp13033-cr-0002" contrib-type="author"><name><surname>Venkatasubramanian</surname><given-names>Sowmya</given-names></name><xref ref-type="aff" rid="bcp13033-aff-0001">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="bcp13033-note-0001">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="bcp13033-cr-0003" contrib-type="author"><name><surname>Pawade</surname><given-names>Tania</given-names></name><xref ref-type="aff" rid="bcp13033-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bcp13033-cr-0004" contrib-type="author"><name><surname>Mitchell</surname><given-names>Andrew J.</given-names></name><xref ref-type="aff" rid="bcp13033-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bcp13033-cr-0005" contrib-type="author"><name><surname>Shah</surname><given-names>Anoop S.</given-names></name><xref ref-type="aff" rid="bcp13033-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bcp13033-cr-0006" contrib-type="author"><name><surname>Lang</surname><given-names>Ninian N.</given-names></name><xref ref-type="aff" rid="bcp13033-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bcp13033-cr-0007" contrib-type="author"><name><surname>Newby</surname><given-names>David E.</given-names></name><xref ref-type="aff" rid="bcp13033-aff-0001">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="bcp13033-note-0002">
<sup>&#x02021;</sup>
</xref></contrib></contrib-group><aff id="bcp13033-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">British Heart Foundation/University Centre for Cardiovascular Science</named-content><institution>University of Edinburgh</institution><named-content content-type="city">Edinburgh</named-content><country country="GB">UK</country></aff><aff id="bcp13033-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences</named-content><institution>University of Glasgow</institution><named-content content-type="city">Glasgow</named-content><country country="GB">UK</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Correspondence<break/>
Dr Colin G. Stirrat, MD, British Heart Foundation/University Centre for Cardiovascular Science, Room SU 305, Chancellor's Building, University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.<break/>
Tel.: +44 013 1242 6515<break/>
Fax: +44 013 1242 6379<break/>
E&#x02010;mail: <email>colin.stirrat@ed.ac.uk</email><break/></corresp><fn id="bcp13033-note-0001"><label>&#x02020;</label><p>
Joint first author.</p></fn><fn id="bcp13033-note-0002"><label>&#x02021;</label><p>
Principal Investigator.</p></fn></author-notes><pub-date pub-type="epub"><day>28</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2016</year></pub-date><volume>82</volume><issue>4</issue><issue-id pub-id-type="doi">10.1111/bcp.v82.4</issue-id><fpage>974</fpage><lpage>982</lpage><history><date date-type="received"><day>26</day><month>10</month><year>2015</year></date><date date-type="rev-recd"><day>26</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>02</day><month>6</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 The British Pharmacological Society <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. British Journal of Clinical Pharmacology published by John Wiley &#x00026; Sons Ltd on behalf of British Pharmacological Society.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:BCP-82-974.pdf"/><abstract><sec id="bcp13033-sec-0001"><title>Aims</title><p>Urocortin 2 and urocortin 3 may play a role in the pathophysiology of heart failure and are emerging therapeutic targets. We aimed to examine the local and systemic cardiovascular effects of urocortin 2 and urocortin 3 in healthy subjects and patients with heart failure.</p></sec><sec id="bcp13033-sec-0002"><title>Methods</title><p>Patients with heart failure (<italic>n</italic>&#x000a0;=&#x000a0;8) and age and gender&#x02010;matched healthy subjects (<italic>n</italic>&#x000a0;=&#x000a0;8) underwent bilateral forearm arterial blood flow measurement using forearm venous occlusion plethysmography during intra&#x02010;arterial infusions of urocortin 2 (3.6&#x02013;36&#x000a0;pmol&#x000a0;min<sup>&#x02212;1</sup>), urocortin 3 (360&#x02013;3600&#x000a0;pmol&#x000a0;min<sup>&#x02212;1</sup>) and substance P (2&#x02013;8&#x000a0;pmol&#x000a0;min<sup>&#x02212;1</sup>). Heart failure patients (<italic>n</italic>&#x000a0;=&#x000a0;9) and healthy subjects (<italic>n</italic>&#x000a0;=&#x000a0;7) underwent non&#x02010;invasive impedance cardiography during incremental intravenous infusions of sodium nitroprusside (573&#x02013;5730&#x000a0;pmol&#x000a0;kg<sup>&#x02212;1</sup>&#x000a0;min<sup>&#x02212;1</sup> ), urocortin 2 (36&#x02013;360&#x000a0;pmol&#x000a0;min<sup>&#x02212;1</sup> ), urocortin 3 (1.2&#x02013;12&#x000a0;nmol&#x000a0;min<sup>&#x02212;1</sup>) and saline placebo.</p></sec><sec id="bcp13033-sec-0003"><title>Results</title><p>Urocortin 2, urocortin 3 and substance P induced dose&#x02010;dependent forearm arterial vasodilatation in both groups (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 for both) with no difference in magnitude of vasodilatation between patients and healthy subjects. During systemic intravenous infusions, urocortin 3 increased heart rate and cardiac index and reduced mean arterial pressure and peripheral vascular resistance index in both groups (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01 for all). Urocortin 2 produced similar responses to urocortin 3, although increases in cardiac index and heart rate were only significant in heart failure (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) and healthy subjects (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001), respectively.</p></sec><sec id="bcp13033-sec-0004"><title>Conclusion</title><p>Urocortins 2 and 3 cause vasodilatation, reduce peripheral vascular resistance and increase cardiac output in both health and disease. These data provide further evidence to suggest that urocortins 2 and 3 continue to hold promise for the treatment of heart failure.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="bcp13033-kwd-0001">cardiac</kwd><kwd id="bcp13033-kwd-0002">heart failure</kwd><kwd id="bcp13033-kwd-0003">inotrope</kwd><kwd id="bcp13033-kwd-0004">urocortin</kwd><kwd id="bcp13033-kwd-0005">vasodilator</kwd></kwd-group><counts><fig-count count="4"/><table-count count="2"/><page-count count="9"/><word-count count="5288"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>bcp13033</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:16.09.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="bcp13033-cit-0000">
<string-name>
<surname>Stirrat</surname>, <given-names>C. G.</given-names>
</string-name>, <string-name>
<surname>Venkatasubramanian</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Pawade</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>, <given-names>A. J.</given-names>
</string-name>, <string-name>
<surname>Shah</surname>, <given-names>A. S.</given-names>
</string-name>, <string-name>
<surname>Lang</surname>, <given-names>N. N.</given-names>
</string-name>, and <string-name>
<surname>Newby</surname>, <given-names>D. E.</given-names>
</string-name> (<year>2016</year>) <article-title>Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure</article-title>. <source>Br J Clin Pharmacol</source>, <volume>82</volume>: <fpage>974</fpage>&#x02013;<lpage>982</lpage>. doi: <ext-link ext-link-type="doi" xlink:href="10.1111/bcp.13033">10.1111/bcp.13033</ext-link>.<pub-id pub-id-type="pmid">27275843</pub-id></mixed-citation>
</p></notes></front><body><sec id="bcp13033-sec-0005"><title>What is Already Known about this Subject</title><p>
<list list-type="bullet" id="bcp13033-list-0001"><list-item id="bcp13033-li-0001"><p>Urocortins 2 and 3 are emerging therapies for treating heart failure.</p></list-item><list-item id="bcp13033-li-0002"><p>Urocortins 2 and 3 reduce peripheral vascular resistance and increase cardiac output in both health and disease.</p></list-item></list>
</p></sec><sec id="bcp13033-sec-0006"><title>What this Study Adds</title><p>
<list list-type="bullet" id="bcp13033-list-0002"><list-item id="bcp13033-li-0003"><p>This is the first direct head&#x02010;to&#x02010;head comparison of urocortin 2 and urocortin 3 in man.</p></list-item><list-item id="bcp13033-li-0004"><p>These data provide further evidence that urocortin 2 and urocortin 3 hold major potential for the treatment of heart failure.</p></list-item></list>
</p></sec><sec id="bcp13033-sec-0007"><title>Introduction</title><p>There are almost six million people living with heart failure in the USA. This comes at an annual cost to the US economy of over $30 billion <xref rid="bcp13033-bib-0001" ref-type="ref">1</xref>. Despite many evidence&#x02010;based therapies for patients with chronic heart failure, treatments for acute heart failure are limited, less well developed and have not been shown to improve clinical outcomes. Indeed the use of inotropic agents has been associated with harm <xref rid="bcp13033-bib-0002" ref-type="ref">2</xref>, <xref rid="bcp13033-bib-0003" ref-type="ref">3</xref>, <xref rid="bcp13033-bib-0004" ref-type="ref">4</xref>. However, the tentative but promising improvements in clinical outcome seen with serelaxin in the recent RELAX&#x02010;AHF study <xref rid="bcp13033-bib-0005" ref-type="ref">5</xref> has renewed enthusiasm for the assessment of novel vasoactive mediators in this important patient group.</p><p>The urocortins are an endogenous peptidic hormone group comprising urocortin 1, urocortin 2 and urocortin 3 with vasodilator, inotropic and lusitropic effects <xref rid="bcp13033-bib-0006" ref-type="ref">6</xref>. Urocortins 2 and 3 counteract many of the effects of corticotrophin&#x02010;releasing hormone (CRH) <xref rid="bcp13033-bib-0007" ref-type="ref">7</xref>, <xref rid="bcp13033-bib-0008" ref-type="ref">8</xref>, <xref rid="bcp13033-bib-0009" ref-type="ref">9</xref>, <xref rid="bcp13033-bib-0010" ref-type="ref">10</xref> and act on the CRH&#x02010;receptor 2 (CRH&#x02010;R2), a G&#x02010;protein coupled receptor that is expressed abundantly in the heart and peripheral vasculature <xref rid="bcp13033-bib-0011" ref-type="ref">11</xref>, <xref rid="bcp13033-bib-0012" ref-type="ref">12</xref>. Urocortin 2 causes vasodilatation in healthy volunteers, augments cardiac output and reduces vascular resistance in healthy humans, patients with acute decompensated, and also chronic stable, heart failure <xref rid="bcp13033-bib-0013" ref-type="ref">13</xref>, <xref rid="bcp13033-bib-0014" ref-type="ref">14</xref>, <xref rid="bcp13033-bib-0015" ref-type="ref">15</xref>, <xref rid="bcp13033-bib-0016" ref-type="ref">16</xref>.</p><p>A recombinant acetate salt of urocortin 3 (JNJ&#x02010;39&#x02009;588&#x02009;146 [recombinant stresscopin]), improved cardiac output whilst reducing vascular resistance in a multicentre study of patients with chronic stable heart failure <xref rid="bcp13033-bib-0017" ref-type="ref">17</xref>. We recently demonstrated that urocortins 2 and 3 increase forearm blood flow in young healthy volunteers <xref rid="bcp13033-bib-0015" ref-type="ref">15</xref>. To date, no clinical study has separated the regional from systemic effects of urocortins 2 and 3 in heart failure or conducted a direct head to head comparison of their effects.</p><p>We aimed to evaluate and compare the local and systemic cardiovascular effects of urocortins 2 and 3 in patients with heart failure and healthy subjects by assessing (i) local forearm arterial blood flow using venous occlusion plethysmography and (ii) cardiac output and vascular resistance using thoracic bioimpedance cardiography. We hypothesized that urocortins 2 and 3 would cause vasodilatation, reduced peripheral vascular resistance and increased cardiac output in both healthy subjects and patients with heart failure.</p></sec><sec id="bcp13033-sec-0008"><title>Methods</title><p>Both studies were approved by the local research ethics committee (South East Scotland REC 01) and carried out in accordance with the Declaration of Helsinki. The registered clinical trials on UKCRN were ID 10749 and 13002.</p><p>Written informed consent was obtained from all participants prior to the study.</p><sec id="bcp13033-sec-0009"><title>Study participants</title><p>Patients with heart failure were eligible if they were aged 18&#x02013;80&#x000a0;years, New York Heart Association (NYHA) symptom class II&#x02013;III and had echocardiographically confirmed left ventricular ejection fraction &#x0003c;35% with left ventricular end diastolic diameter&#x000a0;&#x0003e;&#x000a0;5.5&#x000a0;cm. Patients were required to be receiving maximally tolerated doses of angiotensin&#x02010;converting enzyme inhibitor and &#x003b2;&#x02010;adrenoceptor blocker therapies for at least 3&#x000a0;months. Healthy subjects had no significant previous medical history and were on no regular medications. Exclusion criteria for both groups included systolic blood pressure&#x000a0;&#x0003e;&#x000a0;190&#x000a0;mmHg or &#x0003c;90&#x000a0;mmHg, haemodynamically significant valvular heart disease and other severe or significant co&#x02010;morbidities including bleeding diathesis, renal or hepatic failure, anaemia or recent infective/inflammatory conditions. Women of child bearing potential were also excluded.</p></sec><sec id="bcp13033-sec-0010"><title>Protocol A: local vascular study</title><p>This was a randomized study (Figure&#x000a0;<xref rid="bcp13033-fig-0001" ref-type="fig">1</xref>A) of eight patients with heart failure and eight age and gender&#x02010;matched healthy subjects. Subjects attended once each to receive incremental intra&#x02010;arterial infusions of urocortin 2 (3.6, 12, 36&#x000a0;pmol&#x000a0;min<sup>&#x02212;1</sup>, molecular weight 4450.3&#x000a0;g&#x000a0;mol<sup>&#x02212;1</sup>), urocortin 3 (360, 1200, 3600&#x000a0;pmol&#x000a0;min<sup>&#x02212;1</sup>, molecular weight 4137.9&#x000a0;g&#x000a0;mol<sup>&#x02212;1</sup>) and substance P (2, 4, 8&#x000a0;pmol&#x000a0;min<sup>&#x02212;1</sup> [control endothelium&#x02010;dependent vasodilator]) for 6&#x000a0;min at each dose with a 30&#x000a0;min washout period between agents.</p><fig fig-type="Figure" xml:lang="en" id="bcp13033-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>A) Schematic representation of study protocol A &#x02013; vascular study and B) schematic representation of study protocol B &#x02013; systemic study. A) forearm blood flow. B) systemic haemodynamic responses</p></caption><graphic id="nlm-graphic-1" xlink:href="BCP-82-974-g001"/></fig><p>Forearm venous occlusion plethysmography studies were performed with the subject lying supine, in a quiet, temperature&#x02010;controlled room (22&#x02013;25&#x000b0;C). Participants fasted for 4&#x000a0;h prior to the study and refrained from alcohol and caffeine for 24&#x000a0;h prior to the study. Venous cannulae (17G) were inserted into large subcutaneous veins in the antecubital fossae of both arms at the start of the study to facilitate periodic venous sampling. Heart rate and blood pressure were monitored at regular intervals throughout the study with a semi&#x02010;automated oscillometric sphygmomanometer (Omron 705IT). Participants underwent brachial artery cannulation of the non&#x02010;dominant forearm with a 27 standard wire&#x02010;gauge steel needle for agent infusion. Forearm blood flow was measured in the infused and non&#x02010;infused forearms using bilateral venous occlusion plethysmography as described previously <xref rid="bcp13033-bib-0018" ref-type="ref">18</xref>, <xref rid="bcp13033-bib-0019" ref-type="ref">19</xref>.</p></sec><sec id="bcp13033-sec-0011"><title>Protocol B: systemic study</title><p>This was a randomized, double&#x02010;blind, placebo controlled crossover study (Figure&#x000a0;<xref rid="bcp13033-fig-0001" ref-type="fig">1</xref>B). Three patients with heart failure and three volunteers participants were involved in both studies. Patients with heart failure (<italic>n</italic>&#x000a0;=&#x000a0;9) and healthy subjects (<italic>n</italic>&#x000a0;=&#x000a0;7) were recruited. Participants had venous cannulae inserted into both antecubital fossae and attended on two occasions, receiving intravenous infusions of saline (placebo) or SNP (573, 1909, 5730&#x000a0;pmol&#x000a0;kg<sup>&#x02212;1</sup>&#x000a0;min<sup>&#x02212;1</sup>) followed by either urocortin 2 (36, 108, 360&#x000a0;pmol&#x000a0;min<sup>&#x02212;1</sup>) or urocortin 3 (1.2, 3.6, 12&#x000a0;nmol&#x000a0;min<sup>&#x02212;1</sup>). On the second visit, participants received the two remaining agents not administered on visit 1. Each agent was given in three ascending doses for 10&#x000a0;min at each dose. A 1&#x000a0;h saline washout was given between agents and a further 30&#x000a0;min of saline washout was administered after the cessation of the second agent.</p><sec id="bcp13033-sec-0012"><title>Haemodynamic monitoring</title><p>Haemodynamic measurements were recorded throughout the study. Cardiac output, blood pressure and stroke volume were recorded using non&#x02010;invasive thoracic impedance cardiography (NCCOM3&#x02010;R7, BioMed, CA, USA or Cardioscreen 1000, Medis, Germany) and oscillometric sphygmomanometry (Omron HEM&#x02010;705CP, Omron, Matsusaka, Japan). Values were indexed to body surface area where appropriate and peripheral vascular resistance index was calculated using recorded measurements (PVRI = MAP/CI).</p></sec><sec id="bcp13033-sec-0013"><title>Safety</title><p>Study stopping criteria were in place to ensure participant safety. Criteria included a drop in diastolic blood pressure of &#x0003e;25&#x000a0;mmHg, fall in heart rate below 50&#x000a0;beats&#x000a0;min<sup>&#x02212;1</sup> or rise above 120&#x000a0;beats&#x000a0;min<sup>&#x02212;1</sup>, at the request of the participant, attending nurse or the attending physician.</p></sec><sec id="bcp13033-sec-0014"><title>Venous sampling</title><p>Baseline blood samples were drawn for assessment of full blood count, renal function, glucose and cholesterol concentrations at the start of each study. The local clinical biochemistry and haematology reference laboratories performed analysis.</p></sec><sec id="bcp13033-sec-0015"><title>Data analysis and statistics</title><p>Data were collected in a double&#x02010;blind fashion for both studies. Data were analyzed, where appropriate, by analysis of variance (ANOVA, one way and two way with repeated measures where appropriate). All results in figures are expressed as mean&#x000a0;&#x000b1;&#x000a0;SEM. All statistical analysis was performed with GraphPad Prism, version 6 (GraphPad Software, San Diego, CA, USA). Statistical significance was taken as two&#x02010;sided <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05.</p></sec></sec></sec><sec id="bcp13033-sec-0016"><title>Results</title><p>Patients with heart failure and healthy subjects recruited were predominantly male and middle&#x02010;aged. Heart failure patients had greater BMI compared with healthy subjects. Participant characteristics are shown in Table&#x000a0;<xref rid="bcp13033-tbl-0001" ref-type="table-wrap">1</xref>. Patients with heart failure were receiving maintenance heart failure therapy. Patients and volunteers were age and gender&#x02010;matched in protocol A and age matched alone in protocol B. Three patients with heart failure and three volunteer participants were recruited to both studies.</p><table-wrap id="bcp13033-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Participant characteristics for protocol A and B</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" align="left" valign="bottom" colspan="1"/><th colspan="2" align="left" valign="bottom" rowspan="1">
<bold>Protocol A</bold>
</th><th rowspan="2" align="left" valign="bottom" colspan="1"/><th colspan="2" align="left" valign="bottom" rowspan="1">
<bold>Protocol B</bold>
</th><th rowspan="2" align="left" valign="bottom" colspan="1"/></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Heart failure patients (<italic>n</italic>&#x000a0;=&#x000a0;8)</bold>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Healthy subjects (<italic>n</italic>&#x000a0;=&#x000a0;8)</bold>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Heart failure patients (<italic>n</italic>&#x000a0;=&#x000a0;9)</bold>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Healthy subjects (<italic>n</italic>&#x000a0;=&#x000a0;7)</bold>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Age (years)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">55.5 [52.25&#x02013;67]</td><td align="left" valign="top" rowspan="1" colspan="1">57 [53&#x02013;65.75]</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic>&#x000a0;=&#x000a0;0.84</td><td align="left" valign="top" rowspan="1" colspan="1">58 [50&#x02013;66.5]</td><td align="left" valign="top" rowspan="1" colspan="1">58 [45&#x02013;66]</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<italic>P</italic>&#x000a0;=&#x000a0;0.56</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>BMI</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">30&#x000a0;&#x000b1;&#x000a0;5.4</td><td align="left" valign="top" rowspan="1" colspan="1">25.1&#x000a0;&#x000b1;&#x000a0;2.3</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic>&#x000a0;=&#x000a0;0.03</td><td align="left" valign="top" rowspan="1" colspan="1">32.2&#x000a0;&#x000b1;&#x000a0;4.3</td><td align="left" valign="top" rowspan="1" colspan="1">25.9&#x000a0;&#x000b1;&#x000a0;1.9</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<italic>P</italic>&#x000a0;=&#x000a0;0.003</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Gender</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">5&#x000a0;M, 3F</td><td align="left" valign="top" rowspan="1" colspan="1">5&#x000a0;M, 3F</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">7&#x000a0;M, 2F</td><td align="left" valign="top" rowspan="1" colspan="1">4&#x000a0;M, 3F</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>ACEi/ARB</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">8 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">9 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>BB</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">6 (75)</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">7 (78)</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>MRA</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">5 (63)</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">8 (89)</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Digoxin</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">1 (13)</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">4 (44)</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Loop diuretic</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">6 (75)</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">6 (67)</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Haemoglobin (visit 1 <italic>vs</italic> visit 2, g&#x000a0;l<sup>&#x02212;1</sup>)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">136.0&#x000a0;&#x000b1;&#x000a0;14.46 <italic>vs</italic> 133.0&#x000a0;&#x000b1;&#x000a0;14.96 (<italic>P</italic>&#x000a0;&#x0003e;&#x000a0;0.99)</td><td align="left" valign="top" rowspan="1" colspan="1">143.7&#x000a0;&#x000b1;&#x000a0;7.111 <italic>vs</italic> 135.3&#x000a0;&#x000b1;&#x000a0;8.524 (<italic>P</italic>&#x000a0;&#x0003e;&#x000a0;0.99)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Creatinine (visit 1 <italic>vs</italic> visit 2, &#x003bc;mol&#x000a0;l<sup>&#x02212;1</sup>)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">109.8&#x000a0;&#x000b1;&#x000a0;39.66 <italic>vs</italic> 116.3&#x000a0;&#x000b1;&#x000a0;74.95 (<italic>P</italic>&#x000a0;&#x0003e;&#x000a0;0.99)</td><td align="left" valign="top" rowspan="1" colspan="1">75.29&#x000a0;&#x000b1;&#x000a0;8.635 <italic>vs</italic> 72.67&#x000a0;&#x000b1;&#x000a0;7.840 (<italic>P</italic>&#x000a0;&#x0003e;&#x000a0;0.99)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="bcp13033-note-0003"><p>
<italic>n</italic> (%), mean&#x000a0;&#x000b1;&#x000a0;SD, median [interquartile range]</p></fn></table-wrap-foot></table-wrap><sec id="bcp13033-sec-0017"><title>Protocol A &#x02013; vascular study</title><p>The intra&#x02010;brachial infusion of all three drugs was well tolerated with no adverse effects. Intra&#x02010;brachial infusion of urocortin 2 and 3 produced localized, self&#x02010;limiting forearm flushing and some facial flushing in both groups of participants as noted in previous studies <xref rid="bcp13033-bib-0015" ref-type="ref">15</xref>.</p><p>Urocortin 2, urocortin 3 and substance P all evoked dose&#x02010;dependent forearm arterial vasodilatation in both participant groups (mean changes across the three doses [95%&#x000a0;CI] from baseline as follows: urocortin 2 +60% [9&#x02013;111] <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, +72% [21&#x02013;123] <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01; urocortin 3 +167% [100&#x02013;237] <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001, +151% [82&#x02013;219] <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001; substance P +227% [130&#x02013;326] <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001, +155% [57&#x02013;253] <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001 for healthy controls and heart failure patients, respectively; Figure&#x000a0;<xref rid="bcp13033-fig-0002" ref-type="fig">2</xref>A). There were no significant differences in changes in forearm blood flow between heart failure patients and healthy subjects (urocortin 2 +12% [&#x02212;40 to 63%] <italic>P</italic>&#x000a0;=&#x000a0;0.84, urocortin 3 &#x02212;18% [&#x02212;86 to +50%], <italic>P</italic>&#x000a0;=&#x000a0;0.80; substance P &#x02212;72% [&#x02212;170&#x000a0;&#x02212;&#x000a0;+26%] <italic>P</italic>&#x000a0;+&#x000a0;0.19).</p><fig fig-type="Figure" xml:lang="en" id="bcp13033-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Haemodynamic responses during local administration of urocortin 2, urocortin 3 and substance P (protocol A). A) Percentage change in forearm arterial blood flow to urocortin 2 (3.6&#x02013;36&#x000a0;pmol&#x000a0;min<sup>&#x02212;1</sup>), urocortin 3 (360&#x02013;3600&#x000a0;pmol&#x000a0;min<sup>&#x02212;1</sup>) and substance P (2&#x02013;8&#x000a0;pmol&#x000a0;min<sup>&#x02212;1</sup>) in patients with heart failure (red) and in healthy subjects (black). B) Non&#x02010;invasive systemic hemodynamic responses to intra&#x02010;arterial urocortin 2 (red), urocortin 3 (blue) and substance P (green) in healthy subjects (A) and patients with heart failure (B). (****&#x000a0;=&#x000a0;<italic>P</italic>,0.0001,**&#x000a0;=&#x000a0;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01, *&#x000a0;=&#x000a0;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05)</p></caption><graphic id="nlm-graphic-3" xlink:href="BCP-82-974-g002"/></fig><p>Blood pressure and heart rate remained unchanged in both groups in response to urocortin 2 and substance P. At the highest dose, urocortin 3 induced a transient tachycardia compared with baseline in both groups (heart failure +14.9&#x000a0;beats&#x000a0;min<sup>&#x02212;1</sup> [20.9 to 8.9], healthy volunteers +21.3&#x000a0;mmHg [27.3 to 15.3] both <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) that was accompanied by a drop in systolic (&#x02212;17.4&#x000a0;mmHg [&#x02212;7.9 to &#x02212;26.9], <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) and diastolic blood pressure in patients with heart failure (&#x02212;8.4&#x000a0;mmHg [&#x02212;3.5 to &#x02212;13.3], <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001) and a drop in diastolic blood pressure alone in healthy subjects (&#x02212;12.4&#x000a0;mmHg [&#x02212;7.5 to &#x02212;17.3], <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001, Figure&#x000a0;<xref rid="bcp13033-fig-0002" ref-type="fig">2</xref>B). Non&#x02010;infused forearm blood flow remained unchanged throughout the study (data not shown).</p></sec><sec id="bcp13033-sec-0018"><title>Protocol B &#x02013; systemic study</title><p>Participants displayed hypotension at the higher doses of SNP initially administered in the study (17.2&#x000a0;nmol kg<sup>&#x02212;1</sup>&#x000a0;min<sup>&#x02212;1</sup>), frequently reaching study stopping criteria. A dose reduction to SNP (maximum dose of 5730&#x000a0;pmol&#x000a0;kg<sup>&#x02212;1</sup>&#x000a0;min<sup>&#x02212;1</sup>) was made after two healthy subjects completed the study. For the urocortins, hypotension reaching study stopping criteria was met in one heart failure patient for urocortin 2 and two heart failure patients and one healthy subject for urocortin 3. Participants described dose&#x02010;dependent symptoms of tachycardia and a warm sensation with both urocortins, but there were no significant adverse events attributable to either urocortin 2 or urocortin 3. Full blood count and serum biochemistry was unchanged between the two study visits (Table&#x000a0;<xref rid="bcp13033-tbl-0001" ref-type="table-wrap">1</xref>).</p><p>Urocortin 2 had no significant effect on cardiac index in healthy subjects and heart rate in heart failure patients when compared with saline placebo (<italic>P</italic>&#x000a0;&#x0003e;&#x000a0;0.05 for both, see Figure&#x000a0;<xref rid="bcp13033-fig-0003" ref-type="fig">3</xref> and Table&#x000a0;<xref rid="bcp13033-tbl-0002" ref-type="table-wrap">2</xref> for results). Otherwise urocortin 2 and urocortin 3 increased cardiac index and heart rate and reduced mean arterial pressure and peripheral vascular resistance index in both patients with heart failure and healthy subjects (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 for all). There was no effect of either urocortin 2 or urocortin 3 on stroke volume (<italic>P</italic>&#x000a0;&#x0003e;&#x000a0;0.05 for both).</p><fig fig-type="Figure" xml:lang="en" id="bcp13033-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Changes in haemodynamic responses from baseline following systemic infusion (protocol B). Haemodynamic responses to infusions of urocortin 2, urocortin 3 and SNP in healthy subjects (black) and patients with heart failure (red) at doses 1&#x02013;3 (D1&#x02013;D3). * represents significant differences from saline placebo (not shown) across the three doses (see Table&#x000a0;<xref rid="bcp13033-tbl-0002" ref-type="table-wrap">2</xref>). ^ represents significant differences between participant groups. (****<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001, ***<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, **<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01, *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05; ^^<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01)</p></caption><graphic id="nlm-graphic-5" xlink:href="BCP-82-974-g003"/></fig><table-wrap id="bcp13033-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Results of systemic infusion of urocortin 2 and 3</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" char="[" span="1"/><col align="left" char="[" span="1"/><col align="left" char="[" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Urocortin 2</th><th align="left" valign="bottom" rowspan="1" colspan="1">Urocortin 3</th><th align="left" valign="bottom" rowspan="1" colspan="1">SNP</th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" rowspan="1">
<bold>Healthy volunteers</bold>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<bold>Cardiac index</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">+11.9 [&#x02212;3.1, +26.9] <italic>P</italic>&#x000a0;=&#x000a0;0.17</td><td align="left" valign="top" rowspan="1" colspan="1">+25.4 [+9.8, +41.0]<xref ref-type="fn" rid="bcp13033-note-0006">***</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">+21.7 [+5.5, +37.8]<xref ref-type="fn" rid="bcp13033-note-0007">**</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<bold>Heart rate</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">+17.2 [+7.2, +27.1]<xref ref-type="fn" rid="bcp13033-note-0006">***</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">+25.0 [+14.7, +35.4]<xref ref-type="fn" rid="bcp13033-note-0005">****</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">+29.0 [+18.4, +39.8]<xref ref-type="fn" rid="bcp13033-note-0005">****</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<bold>MAP</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;8.0 [&#x02212;2.6, &#x02212;13.5]<xref ref-type="fn" rid="bcp13033-note-0007">**</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;10.8 [&#x02212;5.1, &#x02212;16.4]<xref ref-type="fn" rid="bcp13033-note-0005">****</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;13.0 [&#x02212;7.2, &#x02212;18.8]<xref ref-type="fn" rid="bcp13033-note-0005">****</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<bold>SV</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.7 [&#x02212;13.8, +6.4] <italic>P</italic>&#x000a0;=&#x000a0;0.77</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;6.3 [&#x02212;16.9, +4.2] <italic>P</italic>&#x000a0;=&#x000a0;0.40</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;6.8 [&#x02212;17.4, +3.9] <italic>P</italic>&#x000a0;=&#x000a0;0.35</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<bold>PVRI</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;17.6 [&#x02212;3.5, &#x02212;31.7]<xref ref-type="fn" rid="bcp13033-note-0007">**</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;23.1 [&#x02212;8.4, &#x02212;37.8]<xref ref-type="fn" rid="bcp13033-note-0006">***</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;22.1 [&#x02212;6.9, &#x02212;37.3]<xref ref-type="fn" rid="bcp13033-note-0007">**</xref>
</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">
<bold>Heart failure</bold>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<bold>Cardiac index</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">+10.1 [+1.0, +19.3]<xref ref-type="fn" rid="bcp13033-note-0008">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">+23.5 [+14.3, +32.7]<xref ref-type="fn" rid="bcp13033-note-0005">****</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">+14.2 [+3.8, +24.7]<xref ref-type="fn" rid="bcp13033-note-0007">**</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<bold>Heart rate</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">+7.1 [&#x02212;0.8, +15.0] <italic>P</italic>&#x000a0;=&#x000a0;0.1</td><td align="left" valign="top" rowspan="1" colspan="1">+18.1 [+10.0 , +26.3]<xref ref-type="fn" rid="bcp13033-note-0005">****</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">+7.4 [&#x02212;1.8, +16.6] <italic>P</italic>&#x000a0;=&#x000a0;0.16</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<bold>MAP</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;4.8 [&#x02212;0.5, &#x02212;9.0]<xref ref-type="fn" rid="bcp13033-note-0008">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;9.1 [&#x02212;4.8, &#x02212;13.5]<xref ref-type="fn" rid="bcp13033-note-0005">****</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;13.6 [&#x02212;8.7, &#x02212;18.5]<xref ref-type="fn" rid="bcp13033-note-0005">****</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<bold>SV</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">+2.7 [&#x02212;2.4, +7.8] <italic>P</italic>&#x000a0;=&#x000a0;0.51</td><td align="left" valign="top" rowspan="1" colspan="1">+4.3 [&#x02212;0.9, +9.5] <italic>P</italic>&#x000a0;=&#x000a0;0.14</td><td align="left" valign="top" rowspan="1" colspan="1">+0.7 [&#x02212;4.8, +6.3] <italic>P</italic>&#x000a0;=&#x000a0;0.99</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>PVRI</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;14.0 [&#x02212;5.3, &#x02212;22.7]<xref ref-type="fn" rid="bcp13033-note-0006">***</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;25.2 [&#x02212;16.2, &#x02212;34.2]<xref ref-type="fn" rid="bcp13033-note-0005">****</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;22.1 [&#x02212;12.2, &#x02212;32.0]<xref ref-type="fn" rid="bcp13033-note-0005">****</xref>
</td></tr></tbody></table><table-wrap-foot><fn id="bcp13033-note-0004"><p>Mean difference [95% CI] of each agent with saline placebo across the three administered doses. * represents significant differences from placebo. (</p></fn><fn id="bcp13033-note-0005"><label>****</label><p>
<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001,</p></fn><fn id="bcp13033-note-0006"><label>***</label><p>
<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001,</p></fn><fn id="bcp13033-note-0007"><label>**</label><p>
<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01,</p></fn><fn id="bcp13033-note-0008"><label>*</label><p>
<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05).</p></fn></table-wrap-foot></table-wrap><p>At the doses used, urocortin 3 caused greater mean increases than urocortin 2 in cardiac index (+13.4 [+4.1 to +22.6], <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01) and heart rate (+11.0 [+2.9 to +19.2], <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01) and greater mean reductions in mean arterial pressure (+4.4 [0.0 to +8.7], <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) and peripheral vascular resistance index (+11.2 [2.2 to +20.1], <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01) in patients with heart failure. No such haemodynamic differences existed between urocortin 2 and urocortin 3 in healthy subjects. No haemodynamic differences existed between participant groups for both urocortin 2 and urocortin 3 (<italic>P</italic>&#x000a0;&#x0003e;&#x000a0;0.05 for all). Following cessation of the intravenous infusions, haemodynamic variables returned to baseline after 40&#x02013;60&#x000a0;min (for example, cardiac index, Figure&#x000a0;<xref rid="bcp13033-fig-0004" ref-type="fig">4</xref>). Over the infusion and washout period, urocortin 3 again caused a greater increase in cardiac output (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) than urocortin 2 in patients with heart failure but not in healthy subjects (<italic>P</italic>&#x000a0;=&#x000a0;0.48).</p><fig fig-type="Figure" xml:lang="en" id="bcp13033-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Duration of haemodynamic response (min) to intravenous urocortin 2 and urocortin 3 (protocol B). Effects of urocortin 2 (red) and urocortin 3 (blue) last 40&#x02013;60&#x000a0;min after cessation of dose 3 (D3) before returning to baseline. At the doses used, urocortin 3 caused a greater increase in cardiac output compared with urocortin 2 in patients with heart failure (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) but not healthy subjects (<italic>P</italic>&#x000a0;=&#x000a0;0.48)</p></caption><graphic id="nlm-graphic-7" xlink:href="BCP-82-974-g004"/></fig></sec></sec><sec id="bcp13033-sec-0019"><title>Discussion</title><p>For the first time, we report the local vascular and systemic effects of urocortins in both patients with heart failure and healthy subjects. We demonstrate that both urocortin 2 and urocortin 3 increase cardiac index and reduce peripheral vascular resistance and their parenteral administration is feasible, safe and well tolerated. We conclude this haemodynamic profile suggests that urocortins 2 and 3 hold major potential for the treatment of acute heart failure.</p><p>Forearm venous occlusion plethysmography combined with intra&#x02010;arterial cannulation allows the assessment of local, sub&#x02010;systemic vasomotor effects of peptides without exerting a systemic response. This is particularly useful in the study of novel compounds, such as urocortin 2 and urocortin 3. We have previously demonstrated that urocortin 2 and 3 cause vasodilatation in healthy subjects and that is in part mediated by endothelium&#x02010;dependent factors such as nitric oxide and endothelium derived hyperpolarizing factor <xref rid="bcp13033-bib-0015" ref-type="ref">15</xref>. Impaired endothelial function is a recognized feature and an independent predictor of adverse outcome in patients with heart failure <xref rid="bcp13033-bib-0020" ref-type="ref">20</xref>, <xref rid="bcp13033-bib-0021" ref-type="ref">21</xref>, <xref rid="bcp13033-bib-0022" ref-type="ref">22</xref>, <xref rid="bcp13033-bib-0023" ref-type="ref">23</xref>, <xref rid="bcp13033-bib-0024" ref-type="ref">24</xref>. There is therefore a theoretical concern that urocortin would be less effective in patients with heart failure because of this concomitant endothelial dysfunction. However, we demonstrate that urocortin 2 and urocortin 3 evoked normal forearm arterial vasodilatory responses in our patients with heart failure. This suggests that either endothelial dysfunction does not have a meaningful impact on the actions of urocortin or our subjects did not have significant endothelial dysfunction. Interestingly, our patients did not demonstrate impaired substance P induced vasodilatation suggesting preserved endothelial function. This may reflect that the patients studied had stable heart failure symptoms and were well&#x02010;treated and receiving optimal medical therapy. Whether similar findings would be observed in patients with decompensated heart failure remains to be established.</p><p>During local intra&#x02010;arterial infusions of the urocortins, we were not anticipating observing any major changes in haemodynamic variables in either group. However, we found dose&#x02010;related increases in heart rate and falls in diastolic blood pressure, especially with urocortin 3 in healthy subjects. This suggests that at the doses used here, we had systemic spill over of urocortin such that we achieved vasoactive blood concentrations outwith the forearm. The doses where systemic systemic spill over was seen helped guide the dosing regime used in protocol B. We have seen systemic spill over previously with other compounds such as substance P <xref rid="bcp13033-bib-0025" ref-type="ref">25</xref> and this is heralded by systemic flushing and rises in the contralateral non&#x02010;infused forearm blood flow. However, here we observed no change in contralateral non&#x02010;infused forearm blood flow although subjects did develop some skin flushing. This suggests that other vascular beds, such as the dermal and splanchnic circulation, are more sensitive to the actions of the urocortins than the forearm circulation. The increase in heart rate at the highest dose of urocortin 3 was less pronounced in patients with heart failure and this was likely due to concomitant &#x003b2;&#x02010;adrenoceptor blocker therapy. Furthermore the associated lower systolic and diastolic blood pressures in this group may be explained by a relative lack of compensatory tachycardia response to vasodilatation in these patients.</p><p>During systemic intravenous infusions, we observed increases in cardiac output with both urocortins. This increase in cardiac output is likely to occur in response to the systemic vasodilatation induced by the urocortins. Although there was no change in stroke volume for either urocortin, this is not a direct measurement of inotropy and we cannot exclude a direct inotropic effect of urocortin on the heart, as previously seen with urocortin 2 in rodents <xref rid="bcp13033-bib-0026" ref-type="ref">26</xref>. At the doses we administered, urocortin 3 exerted more marked haemodynamic effects than urocortin 2 in patients but not healthy subjects. This may reflect the differences in doses we employed, but may also reflect important differences between these two agents. This needs further exploration to determine which urocortin subtype is the most promising for clinical therapeutic development.</p><p>Differences in biological effects between the urocortins can be explained by the structural differences that exist between the two agents, generating conformational changes in the G protein coupled receptor, in turn altering secondary messenger systems that are responsible for creating the biological effects seen. However it may not be this simple and there may be other systems involved. Promising preclinical studies suggest a role for the urocortins in the inhibition of cardiac sympathetic nerve activity [SNA] <xref rid="bcp13033-bib-0027" ref-type="ref">27</xref>, <xref rid="bcp13033-bib-0028" ref-type="ref">28</xref>, often overactive in patients with heart failure. Although Ucn2 has been reported to increase skeletal muscle SNA in humans <xref rid="bcp13033-bib-0029" ref-type="ref">29</xref>, this should not necessarily be seen as a discrepant finding as SNA responses typically are regionally differentiated.</p><p>Increases in heart rate have not been reported in recent studies with urocortin 2/stresscopin <xref rid="bcp13033-bib-0016" ref-type="ref">16</xref>, <xref rid="bcp13033-bib-0017" ref-type="ref">17</xref>. However higher doses of urocortin 2 <xref rid="bcp13033-bib-0014" ref-type="ref">14</xref>, comparable with the doses we have used here, saw similar increases in heart rate.</p><p>There may be concern regarding the clinical use of a heart failure therapy that is both positively chronotropic and inotropic. This combination of effects might predispose to increased myocardial oxygen consumption and potential arrhythmia, particularly in patients with coronary artery disease. We observed no episodes of arrhythmia or adverse effects in our study and, indeed, urocortin 2 has been shown to have anti&#x02010;arrhythmic effects that would be hugely beneficial in treating this group of patients <xref rid="bcp13033-bib-0030" ref-type="ref">30</xref>, <xref rid="bcp13033-bib-0031" ref-type="ref">31</xref>. However, our infusions were brief and adverse effects may be seen with longer infusions or in those patients with decompensated heart failure. In addition, avoidance of significant hypotension remains an important consideration, especially in patients with already low perfusion pressure or renal impairment. Results from our study suggest that dose titration during administration may be needed to optimize cardiac output and vasodilatory responses, whilst avoiding the unwanted effects of significant tachycardia or hypotension.</p><sec id="bcp13033-sec-0020"><title>Study limitations</title><p>This study included only patients with stable heart failure who were prescribed evidence&#x02010;based heart failure therapy that may have affected the response of these agents. However, there was no evidence of diminished effect with concomitant medical therapy in patients with heart failure. We did not include patients with acute decompensated heart failure but we did compare with healthy control subjects, not used in a similar sized study with urocortin 2 <xref rid="bcp13033-bib-0014" ref-type="ref">14</xref>. Although our results cannot be extrapolated to the setting of acute heart failure, there appears to be no reason why the beneficial effects seen in this study cannot be replicated in the acute heart failure setting provided an appropriate, controlled dosing regime is used. Furthermore studies using urocortin 2, and derivatives thereof, in the acute setting have already been carried out successfully. There does however remain a clear need for urocortin 3 to be trialled in this group of patients.</p><p>We observed increases in cardiac index in protocol B but it should be reinforced that this study was not designed to compare the relative contributions of chonotropy, inotropy and vasodilatation to the changes in cardiac index we recorded. Invasive studies would be required for this. Furthermore, the molar concentrations of urocortin 2 and urocortin 3 at each dose were different and differences in efficacy may reflect the differences in dose used and not true differences in potency.</p><p>Finally although there was no change in stroke volume for either agent, we did not conduct invasive haemodynamic monitoring which would be required for assessment of true inotropy and also useful for assessment of pulmonary capillary wedge pressure (PCWP). Surprisingly two recent studies did not detect a statistically significant reduction in PCWP in patients with heart failure with either urocortin 2/stresscopin <xref rid="bcp13033-bib-0016" ref-type="ref">16</xref>, <xref rid="bcp13033-bib-0017" ref-type="ref">17</xref>. However a clear trend toward a reduction in PCWP was seen in both studies.</p><p>In conclusion, we demonstrate that both urocortin 2 and urocortin 3 increase cardiac index and reduce peripheral vascular resistance. Their parenteral administration was feasible, safe and well tolerated. We conclude that these data provide further evidence suggesting urocortin 2 and urocortin 3 continue to hold promise for the treatment of heart failure.</p></sec></sec><sec id="bcp13033-sec-0021"><title>Competing Interests</title><p>All authors have completed the Unified Competing Interest form at <ext-link ext-link-type="uri" xlink:href="http://www.icmje.org/coi_disclosure.pdf">www.icmje.org/coi_disclosure.pdf</ext-link> (available on request from the corresponding author) and declare no support from any organization for the submitted work, no financial relationships with any organizations that might have an interest in the submitted work in the previous 3&#x000a0;years and no other relationships or activities that could appear to have influenced the submitted work.</p></sec></body><back><ref-list id="bcp13033-bibl-0001" content-type="cited-references"><title>References</title><ref id="bcp13033-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="bcp13033-cit-0002">
<string-name>
<surname>Mozaffarian</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Benjamin</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Go</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Arnett</surname>
<given-names>DK</given-names>
</string-name>, <string-name>
<surname>Blaha</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Cushman</surname>
<given-names>M</given-names>
</string-name>, <italic>et al.</italic>
<article-title>Heart disease and stroke statistics&#x02010;&#x02010;2015 update: a report from the American Heart Association</article-title>. <source>Circulation</source>
<year>2015</year>; <volume>131</volume>: <fpage>e29</fpage>&#x02013;<lpage>322</lpage>.<pub-id pub-id-type="pmid">25520374</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="bcp13033-cit-0003">
<string-name>
<surname>Elkayam</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Tasissa</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Binanay</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Stevenson</surname>
<given-names>LW</given-names>
</string-name>, <string-name>
<surname>Gheorghiade</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Warnica</surname>
<given-names>JW</given-names>
</string-name>, <italic>et al.</italic>
<article-title>Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure</article-title>. <source>Am Heart J</source>
<year>2007</year>; <volume>153</volume>: <fpage>98</fpage>&#x02013;<lpage>104</lpage>.<pub-id pub-id-type="pmid">17174645</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="bcp13033-cit-0004">
<string-name>
<surname>Felker</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Benza</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Chandler</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Leimberger</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Cuffe</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Califf</surname>
<given-names>RM</given-names>
</string-name>, <italic>et al.</italic>
<article-title>Heart failure etiology and response to milrinone in decompensated heart failure &#x02010; Results from the OPTIME&#x02010;CHF study</article-title>. <source>J Am Coll Cardiol</source>
<year>2003</year>; <volume>41</volume>: <fpage>997</fpage>&#x02013;<lpage>1003</lpage>.<pub-id pub-id-type="pmid">12651048</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="bcp13033-cit-0005">
<string-name>
<surname>Cuffe</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Califf</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Adams</surname>
<given-names>KF</given-names>
</string-name>, <string-name>
<surname>Benza</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bourge</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Colucci</surname>
<given-names>WS</given-names>
</string-name>, <italic>et al.</italic>
<article-title>Short&#x02010;term intravenous milrinone for acute exacerbation of chronic heart failure &#x02010; A randomized controlled trial</article-title>. <source>JAMA</source>
<year>2002</year>; <volume>287</volume>: <fpage>1541</fpage>&#x02013;<lpage>1547</lpage>.<pub-id pub-id-type="pmid">11911756</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="bcp13033-cit-0006">
<string-name>
<surname>Teerlink</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Cotter</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Davison</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Felker</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Filippatos</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Greenberg</surname>
<given-names>BH</given-names>
</string-name>, <italic>et al.</italic>
<article-title>Serelaxin, recombinant human relaxin&#x02010;2, for treatment of acute heart failure (RELAX&#x02010;AHF): a randomised, placebo&#x02010;controlled trial</article-title>. <source>Lancet</source>
<year>2013</year>; <volume>381</volume>: <fpage>29</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">23141816</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="bcp13033-cit-0007">
<string-name>
<surname>Venkatasubramanian</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Newby</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Lang</surname>
<given-names>NN</given-names>
</string-name>. <article-title>Urocortins in heart failure</article-title>. <source>Biochem Pharmacol</source>
<year>2010</year>; <volume>80</volume>: <fpage>289</fpage>&#x02013;<lpage>296</lpage>.<pub-id pub-id-type="pmid">20363214</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="bcp13033-cit-0008">
<string-name>
<surname>Rademaker</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Charles</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Espiner</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Frampton</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Kirkpatrick</surname>
<given-names>CMJ</given-names>
</string-name>, <italic>et al.</italic>
<article-title>Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep</article-title>. <source>J Am Coll Cardiol</source>
<year>2002</year>; <volume>40</volume>: <fpage>1495</fpage>&#x02013;<lpage>1505</lpage>.<pub-id pub-id-type="pmid">12392842</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="bcp13033-cit-0009">
<string-name>
<surname>Rademaker</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Cameron</surname>
<given-names>VA</given-names>
</string-name>, <string-name>
<surname>Charles</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Richards</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure</article-title>. <source>Circulation</source>
<year>2005</year>; <volume>112</volume>: <fpage>3624</fpage>&#x02013;<lpage>3632</lpage>.<pub-id pub-id-type="pmid">16330704</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="bcp13033-cit-0010">
<string-name>
<surname>Rademaker</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Cameron</surname>
<given-names>VA</given-names>
</string-name>, <string-name>
<surname>Charles</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Richards</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure</article-title>. <source>Eur Heart J</source>
<year>2006</year>; <volume>27</volume>: <fpage>2088</fpage>&#x02013;<lpage>2098</lpage>.<pub-id pub-id-type="pmid">16825287</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="bcp13033-cit-0011">
<string-name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Totsune</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Murakami</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Saruta</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nakabayashi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Suzuki</surname>
<given-names>T</given-names>
</string-name>, <italic>et al.</italic>
<article-title>Expression of urocortin III/stresscopin in human heart and kidney</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2004</year>; <volume>89</volume>: <fpage>1897</fpage>&#x02013;<lpage>1903</lpage>.<pub-id pub-id-type="pmid">15070962</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="bcp13033-cit-0012">
<string-name>
<surname>Wiley</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Davenport</surname>
<given-names>AP</given-names>
</string-name>. <article-title>CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators</article-title>. <source>Br J Pharmacol</source>
<year>2004</year>; <volume>143</volume>: <fpage>508</fpage>&#x02013;<lpage>514</lpage>.<pub-id pub-id-type="pmid">15381637</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="bcp13033-cit-0013">
<string-name>
<surname>Kimura</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Expression of urocortin and corticotropin&#x02010;releasing factor receptor subtypes in the human heart</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2002</year>; <volume>87</volume>: <fpage>340</fpage>&#x02013;<lpage>346</lpage>.<pub-id pub-id-type="pmid">11788672</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="bcp13033-cit-0014">
<string-name>
<surname>Davis</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Pemberton</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Yandle</surname>
<given-names>TG</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>
<given-names>SF</given-names>
</string-name>, <string-name>
<surname>Lainchbury</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Frampton</surname>
<given-names>CM</given-names>
</string-name>, <italic>et al.</italic>
<article-title>Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses</article-title>. <source>J Am Coll Cardiol</source>
<year>2007</year>; <volume>49</volume>: <fpage>461</fpage>&#x02013;<lpage>471</lpage>.<pub-id pub-id-type="pmid">17258092</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="bcp13033-cit-0015">
<string-name>
<surname>Davis</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Pemberton</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Yandle</surname>
<given-names>TG</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>
<given-names>SF</given-names>
</string-name>, <string-name>
<surname>Lainchbury</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Frampton</surname>
<given-names>CM</given-names>
</string-name>, <italic>et al.</italic>
<article-title>Urocortin 2 infusion in human heart failure</article-title>. <source>Eur Heart J</source>
<year>2007</year>; <volume>28</volume>: <fpage>2589</fpage>&#x02013;<lpage>2597</lpage>.<pub-id pub-id-type="pmid">17720993</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="bcp13033-cit-0016">
<string-name>
<surname>Venkatasubramanian</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Griffiths</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>McLean</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Luo</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lang</surname>
<given-names>NN</given-names>
</string-name>, <italic>et al.</italic>
<article-title>Vascular effects of urocortins 2 and 3 in healthy volunteers</article-title>. <source>J Am Heart Assoc</source>
<year>2013</year>; <volume>2</volume>: <fpage>e004267</fpage>.<pub-id pub-id-type="pmid">23525432</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="bcp13033-cit-0017">
<string-name>
<surname>Chan</surname>
<given-names>WYW</given-names>
</string-name>, <string-name>
<surname>Frampton</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Crozier</surname>
<given-names>IG</given-names>
</string-name>, <string-name>
<surname>Troughton</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Richards</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Urocortin&#x02010;2 infusion in acute decompensated heart failure: findings from the UNICORN study (urocortin&#x02010;2 in the treatment of acute heart failure as an adjunct over conventional therapy)</article-title>. <source>JACC Heart Fail</source>
<year>2013</year>; <volume>1</volume>: <fpage>433</fpage>&#x02013;<lpage>441</lpage>.<pub-id pub-id-type="pmid">24621976</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="bcp13033-cit-0018">
<string-name>
<surname>Gheorghiade</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Greene</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Ponikowski</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Maggioni</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Korewicki</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Macarie</surname>
<given-names>C</given-names>
</string-name>, <italic>et al.</italic>
<article-title>Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction</article-title>. <source>Eur J Heart Fail</source>
<year>2013</year>; <volume>15</volume>: <fpage>679</fpage>&#x02013;<lpage>689</lpage>.<pub-id pub-id-type="pmid">23471413</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="bcp13033-cit-0019">
<string-name>
<surname>Newby</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Wright</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Ludlam</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Fox</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Boon</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Webb</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>An <italic>in vivo</italic> model for the assessment of acute fibrinolytic capacity of the endothelium</article-title>. <source>Thromb Haemost</source>
<year>1997</year>; <volume>78</volume>: <fpage>1242</fpage>&#x02013;<lpage>1248</lpage>.<pub-id pub-id-type="pmid">9364992</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="bcp13033-cit-0020">
<string-name>
<surname>Newby</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Wright</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Labinjoh</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ludlam</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Fox</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Boon</surname>
<given-names>NA</given-names>
</string-name>, <italic>et al.</italic>
<article-title>Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction</article-title>. <source>Circulation</source>
<year>1999</year>; <volume>99</volume>: <fpage>1411</fpage>&#x02013;<lpage>1415</lpage>.<pub-id pub-id-type="pmid">10086962</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="bcp13033-cit-0021">
<string-name>
<surname>Katz</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Biasucci</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sabba</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Strom</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Jondeau</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Galvao</surname>
<given-names>M</given-names>
</string-name>, <italic>et al.</italic>
<article-title>Impaired endothelium&#x02010;mediated vasodilation in the peripheral vasculature of patients with congestive heart failure</article-title>. <source>J Am Coll Cardiol</source>
<year>1992</year>; <volume>19</volume>: <fpage>918</fpage>&#x02013;<lpage>925</lpage>.<pub-id pub-id-type="pmid">1552112</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="bcp13033-cit-0022">
<string-name>
<surname>Kubo</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Rector</surname>
<given-names>TS</given-names>
</string-name>, <string-name>
<surname>Bank</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Heifetz</surname>
<given-names>SM</given-names>
</string-name>. <article-title>Endothelium&#x02010;dependent vasodilation is attenuated in patients with heart failure</article-title>. <source>Circulation</source>
<year>1991</year>; <volume>84</volume>: <fpage>1589</fpage>&#x02013;<lpage>1596</lpage>.<pub-id pub-id-type="pmid">1914099</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="bcp13033-cit-0023">
<string-name>
<surname>Yang</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kong</surname>
<given-names>J</given-names>
</string-name>. <article-title>The endothelium as a target for the treatment of heart failure</article-title>. <source>Cell Biochem Biophys</source>
<year>2015</year>; <volume>1&#x02013;6</volume>.</mixed-citation></ref><ref id="bcp13033-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="bcp13033-cit-0024">
<string-name>
<surname>de Berrazueta</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Guerra&#x02010;Ruiz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Garc&#x000ed;a&#x02010;Unzueta</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Toca</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Laso</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>de Adana</surname>
<given-names>MS</given-names>
</string-name>, <italic>et al.</italic>
<article-title>Endothelial dysfunction, measured by reactive hyperaemia using strain&#x02010;gauge plethysmography, is an independent predictor of adverse outcome in heart failure</article-title>. <source>Eur J Heart Fail</source>
<year>2010</year>; <volume>12</volume>: <fpage>477</fpage>&#x02013;<lpage>483</lpage>.<pub-id pub-id-type="pmid">20354033</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="bcp13033-cit-0025">
<string-name>
<surname>Takishima</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hirano</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kitta</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kobayashi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fujioka</surname>
<given-names>D</given-names>
</string-name>, <italic>et al.</italic>
<article-title>Predictive value of serial assessment of endothelial function in chronic heart failure</article-title>. <source>Int J Cardiol</source>
<year>2012</year>; <volume>158</volume>: <fpage>417</fpage>&#x02013;<lpage>422</lpage>.<pub-id pub-id-type="pmid">21371765</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="bcp13033-cit-0026">
<string-name>
<surname>Newby</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Sciberras</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Mendel</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Gertz</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Boon</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Webb</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Intra&#x02010;arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability</article-title>. <source>Br J Clin Pharmacol</source>
<year>1997</year>; <volume>43</volume>: <fpage>493</fpage>&#x02013;<lpage>499</lpage>.<pub-id pub-id-type="pmid">9159564</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="bcp13033-cit-0027">
<string-name>
<surname>Bale</surname>
<given-names>TL</given-names>
</string-name>, <string-name>
<surname>Hoshijima</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Dalton</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>KF</given-names>
</string-name>, <italic>et al.</italic>
<article-title>The cardiovascular physiologic actions of urocortin II: Acute effects in murine heart failure</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>2004</year>; <volume>101</volume>: <fpage>3697</fpage>&#x02013;<lpage>3702</lpage>.<pub-id pub-id-type="pmid">14990799</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="bcp13033-cit-0028">
<string-name>
<surname>Charles</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Jardine</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Rademaker</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Richards</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Urocortin 2 induces potent long&#x02010;lasting inhibition of cardiac sympathetic drive despite baroreflex activation in conscious sheep</article-title>. <source>J Endocrinol</source>
<year>2010</year>; <volume>204</volume>: <fpage>181</fpage>&#x02013;<lpage>189</lpage>.<pub-id pub-id-type="pmid">19914944</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="bcp13033-cit-0029">
<string-name>
<surname>Charles</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Jardine</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Rademaker</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Richards</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Urocortin 3 inhibits cardiac sympathetic nerve activity in conscious sheep</article-title>. <source>J Cardiovasc Pharmacol</source>
<year>2011</year>; <volume>58</volume>: <fpage>418</fpage>&#x02013;<lpage>423</lpage>.<pub-id pub-id-type="pmid">21697721</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="bcp13033-cit-0030">
<string-name>
<surname>Chan</surname>
<given-names>WYW</given-names>
</string-name>, <string-name>
<surname>Charles</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Frampton</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Richards</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Crozier</surname>
<given-names>IG</given-names>
</string-name>, <string-name>
<surname>Troughton</surname>
<given-names>RW</given-names>
</string-name>, <italic>et al.</italic>
<article-title>Human muscle sympathetic nerve responses to urocortin&#x02010;2 in health and stable heart Ffailure</article-title>. <source>Clin Exp Pharmacol Physiol</source>
<year>2015</year>. doi: <ext-link ext-link-type="doi" xlink:href="10.1111/1440-1681.12449">10.1111/1440-1681.12449</ext-link>.</mixed-citation></ref><ref id="bcp13033-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="bcp13033-cit-0031">
<string-name>
<surname>Meili&#x02010;Butz</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>B&#x000fc;hler</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>John</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Buser</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Vale</surname>
<given-names>WW</given-names>
</string-name>, <string-name>
<surname>Peterson</surname>
<given-names>KL</given-names>
</string-name>, <italic>et al.</italic>
<article-title>Acute effects of urocortin 2 on cardiac function and propensity for arrhythmias in an animal model of hypertension&#x02010;induced left ventricular hypertrophy and heart failure</article-title>. <source>Eur J Heart Fail</source>
<year>2010</year>; <volume>12</volume>: <fpage>797</fpage>&#x02013;<lpage>804</lpage>.<pub-id pub-id-type="pmid">20388649</pub-id></mixed-citation></ref><ref id="bcp13033-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="bcp13033-cit-0032">
<string-name>
<surname>Liu</surname>
<given-names>C&#x02010;N</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>X&#x02010;Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>S</given-names>
</string-name>. <article-title>
<italic>In vivo</italic> protective effects of urocortin on ischemia&#x02013;reperfusion injury in rat heart via free radical mechanisms</article-title>. <source>Can J Physiol Pharmacol</source>
<year>2005</year>; <volume>83</volume>: <fpage>459</fpage>&#x02013;<lpage>465</lpage>.<pub-id pub-id-type="pmid">16049545</pub-id></mixed-citation></ref></ref-list></back></article>